

-26-

**WHAT IS CLAIMED IS**

1. A formulation for targeting an infectious agent which acquires a HLA-DR host membrane protein during its life cycle or a HLA-DR expressing host cell or both, said  
5 formulation comprising a ligand capable of binding to said host membrane protein, said ligand being coupled to a lipid-comprising vesicle.

2. A formulation according to claim 1 wherein lipid-comprising vesicle is a liposome.  
10

3. A formulation according to claim 2 wherein said liposome comprises a mixture of diacylphosphatidylcholine and diacylphosphatidylglycerol in a molar ratio ranging between 10:1 and 1:1, wherein the acyl chains are either saturated or unsaturated and have between 14 and 18 carbon atoms in length.  
15

4. A formulation according to claim 3, wherein said lipid component comprises a polyethyleneglycol derivative of diacylphosphatidylethanolamine.

5. A formulation according to claim 4, wherein the polyethyleneglycol has a  
20 molecular weight comprises between about 500 and 5000 daltons.

6. A formulation according to claim 3, wherein the molar ratio is 10:3.

7. A formulation according to claim 4 or 5, wherein said lipid component  
25 comprises a mixture of diacylphosphatidylcholine:diacylphosphatidylglycerol:diacylphosphatidylethanol-amine-polyethyleneglycol in a molar ratio of 10:3:0.1-3.

8. A formulation according to claim 2, 3 or 6, wherein said lipid component  
30 comprises a mixture of dipalmitoylphosphatidylcholine:dipalmitoylphosphatidylglycerol in a molar ratio of 10:3 or distearoylphosphatidylcholine:distearoylphosphatidylglycerol in a molar ratio of 10:3.

9. A formulation according to claim 2, 3, 4, 5 or 7, wherein said lipid component  
35 comprises a mixture of dipalmitoylphosphatidylcholine:dipalmitoylphosphatidylglycerol:dipalmitoylphosphatidylethanolamine-polyethyleneglycol in a molar ratio of 10:3:0.33 or dipalmitoylphosphatidylcholine:dipalmitoylphosphatidylglycerol:distearoylphosphatidylethanolamine-polyethyleneglycol in a molar ratio of 10:3:0.83.

**ART 34 AMDT**

[illegible]

- ART 34 AMDT

-28-

21. The use of a formulation according to any one of claims 1 to 20 for treating or preventing a disease caused by said infectious agent.

22. The use of a ligand to a host membrane protein which is acquired by an infectious agent during its life cycle in the making of a formulation for targeting said infectious agent and its host cell, said ligand being coupled to a lipid-comprising vesicle and said protein does not consist of CD4 or of a HLA class 1 protein.

23. The use as defined in claim 22, wherein said formulation is defined in any one of claims 1 to 20.

00922374.4(03-05-2000) - CA00/00469(03-05-2000)

ART 34 AMDT